10x Genomics (TXG) Financials

$9.49 +0.15 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$9.55 +0.06 (+0.63%)

As of 07:56 PM Eastern

Annual Income Statements for 10x Genomics

This table shows 10x Genomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Income / (Loss) Attributable to Common Shareholders	-183	-255	-166	-58	-543	-31	-112	-19
Consolidated Net Income / (Loss)	-183	-255	-166	-58	-543	-31	-112	-19
Net Income / (Loss) Continuing Operations	-183	-255	-166	-58	-543	-31	-112	-19
Total Pre-Tax Income	-178	-249	-162	-54	-534	-31	-112	-19
Total Operating Income	-195	-265	-168	-52	-534	-31	-111	-18
Total Gross Profit	414	409	396	416	240	185	118	61
Total Revenue	611	619	516	490	299	246	146	71
Operating Revenue	611	619	516	490	299	246	146	71
Total Cost of Revenue	196	209	120	74	58	61	29	11
Operating Cost of Revenue	196	209	120	74	58	61	29	11
Total Operating Expenses	609	675	564	469	775	215	228	79
Selling, General & Admin Expense	344	343	298	258	202	131	88	47
Research & Development Expense	265	331	266	212	571	83	110	32
Total Other Income / (Expense), net	17	17	5.97	-1.46	1.19	-0.46	-1.63	-0.37
Interest & Investment Income	18	17	6.65	0.21	1.53	2.81	1.02	0.31
Other Income / (Expense), net	-1.59	-0.31	-0.20	-0.80	1.34	-0.19	-0.25	0.14
Income Tax Expense	4.93	6.34	4.03	4.51	8.26	0.22	0.09	0.02
Basic Earnings per Share	($1.52)	($2.18)	($1.46)	($0.53)	($5.37)	($0.80)	($8.40)	($1.62)
Weighted Average Basic Shares Outstanding	120.45M	117.17M	113.86M	110.35M	101.15M	39.09M	13.39M	11.59M
Diluted Earnings per Share	($1.52)	($2.18)	($1.46)	($0.53)	($5.37)	($0.80)	($8.40)	($1.62)
Weighted Average Diluted Shares Outstanding	120.45M	117.17M	113.86M	110.35M	101.15M	39.09M	13.39M	11.59M
Weighted Average Basic & Diluted Shares Outstanding	122.30M	119.17M	115.36M	112.84M	101.15M	39.09M	13.39M	11.59M

This table shows 10x Genomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-34	-49	-36	-38	-60	-49	-93	-62	-51	-17	-42
Consolidated Net Income / (Loss)	-34	-49	-36	-38	-60	-49	-93	-62	-51	-17	-42
Net Income / (Loss) Continuing Operations	-34	-49	-36	-38	-60	-49	-93	-62	-51	-17	-42
Total Pre-Tax Income	-34	-48	-34	-37	-58	-47	-92	-61	-50	-16	-40
Total Operating Income	-39	-50	-41	-42	-61	-55	-95	-63	-52	-23	-40
Total Gross Profit	105	111	106	104	93	116	96	100	98	119	101
Total Revenue	155	165	152	153	141	184	154	147	134	156	131
Operating Revenue	155	165	152	153	141	184	154	147	134	156	131
Total Cost of Revenue	49	54	45	49	48	68	58	47	36	37	30
Operating Cost of Revenue	49	54	45	49	48	68	58	47	36	37	30
Total Operating Expenses	145	161	148	146	154	171	190	163	150	143	141
Selling, General & Admin Expense	90	94	82	83	86	86	82	92	83	79	73
Research & Development Expense	64	67	66	63	69	85	108	71	67	64	67
Other Operating Expenses / (Income)	-9.20	-	-	-	-	-	-	-	-	-	-
Total Other Income / (Expense), net	5.82	1.46	7.05	4.66	3.70	8.59	3.05	2.59	2.33	6.29	-0.04
Interest Expense	0.00	-	-	-	0.00	-	-	-	0.02	-	0.11
Interest & Investment Income	3.69	4.03	4.97	4.72	4.74	4.64	4.30	4.10	3.87	2.82	2.03
Other Income / (Expense), net	2.14	-2.57	2.08	-0.06	-1.04	3.96	-1.25	-1.50	-1.52	-	-1.95
Income Tax Expense	0.85	0.65	1.32	0.82	2.15	2.35	1.24	1.65	1.09	0.80	1.88
Basic Earnings per Share	($0.28)	($0.40)	($0.30)	($0.32)	($0.50)	($0.42)	($0.79)	($0.53)	($0.44)	($0.14)	($0.37)
Weighted Average Basic Shares Outstanding	122.61M	120.45M	120.73M	120.07M	119.39M	117.17M	117.73M	116.71M	115.62M	113.86M	114.11M
Diluted Earnings per Share	($0.28)	($0.40)	($0.30)	($0.32)	($0.50)	($0.42)	($0.79)	($0.53)	($0.44)	($0.14)	($0.37)
Weighted Average Diluted Shares Outstanding	122.61M	120.45M	120.73M	120.07M	119.39M	117.17M	117.73M	116.71M	115.62M	113.86M	114.11M
Weighted Average Basic & Diluted Shares Outstanding	123.13M	122.30M	121.05M	120.49M	119.71M	119.17M	118.21M	117.42M	116.19M	115.36M	114.46M

This table details how cash moves in and out of 10x Genomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Change in Cash & Equivalents	-15	132	-369	-93	212	406	22	6.11
Net Cash From Operating Activities	6.66	-15	-34	-21	-218	35	-76	-11
Net Cash From Continuing Operating Activities	6.66	-15	-34	-21	-218	35	-76	-11
Net Income / (Loss) Continuing Operations	-183	-255	-166	-58	-543	-31	-112	-19
Consolidated Net Income / (Loss)	-183	-255	-166	-58	-543	-31	-112	-19
Depreciation Expense	36	36	25	21	14	7.07	3.91	4.31
Amortization Expense	7.83	8.11	7.64	7.14	5.03	0.10	0.46	0.15
Non-Cash Adjustments To Reconcile Net Income	144	179	137	96	356	14	3.70	1.66
Changes in Operating Assets and Liabilities, net	1.78	18	-37	-87	-50	45	28	1.95
Net Cash From Investing Activities	-33	133	-351	-107	-38	-43	-6.71	-3.76
Net Cash From Continuing Investing Activities	-33	133	-351	-107	-38	-43	-6.71	-3.76
Purchase of Property, Plant & Equipment	-12	-49	-132	-101	-37	-43	-6.28	-3.76
Acquisitions	-1.00	-0.92	-4.00	-5.45	-1.73	-0.03	-0.43	0.00
Purchase of Investments	-49	0.00	-283	0.00	0.00	-	-	-
Sale and/or Maturity of Investments	30	183	68	0.00	0.00	-	-	-
Net Cash From Financing Activities	11	14	16	35	469	415	105	21
Net Cash From Continuing Financing Activities	11	14	16	35	469	415	105	21
Repayment of Debt	0.00	-5.81	-5.41	-5.03	-37	-11	-0.70	0.00
Issuance of Common Equity	11	19	21	40	482	411	0.00	0.00
Effect of Exchange Rate Changes	-0.16	-0.03	-0.04	0.23	-0.46	-0.05	-0.02	-0.01
Cash Interest Paid	0.00	0.44	0.84	1.22	1.67	2.25	1.82	0.66
Cash Income Taxes Paid	5.64	4.93	3.93	8.66	0.28	0.02	0.01	0.00

This table details how cash moves in and out of 10x Genomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	33	-54	18	24	-3.50	45	-16	-8.94	112	-14	-40
Net Cash From Operating Activities	34	-6.75	22	7.50	-16	26	-25	-12	-4.13	14	-9.56
Net Cash From Continuing Operating Activities	34	-6.75	22	7.50	-16	26	-25	-12	-4.13	14	-9.56
Net Income / (Loss) Continuing Operations	-34	-49	-36	-38	-60	-49	-93	-62	-51	-17	-42
Consolidated Net Income / (Loss)	-34	-49	-36	-38	-60	-49	-93	-62	-51	-17	-42
Depreciation Expense	8.02	8.75	8.96	8.97	9.19	9.72	9.37	9.94	6.48	6.52	6.16
Amortization Expense	1.79	1.81	1.79	1.93	2.30	1.99	2.05	1.94	2.13	1.95	1.96
Non-Cash Adjustments To Reconcile Net Income	31	33	34	38	39	46	40	48	44	41	34
Changes in Operating Assets and Liabilities, net	28	-1.42	13	-4.00	-5.85	17	16	-9.47	-5.81	-19	-9.28
Net Cash From Investing Activities	-1.89	-52	-3.62	12	11	13	4.90	-4.46	120	-33	-33
Net Cash From Continuing Investing Activities	-1.89	-52	-3.62	12	11	13	4.90	-4.46	120	-33	-33
Purchase of Property, Plant & Equipment	-1.89	-2.72	-3.89	-2.88	-2.91	-3.45	-15	-25	-4.56	-40	-37
Sale and/or Maturity of Investments	0.00	-	0.27	16	14	17	20	21	125	9.06	17
Net Cash From Financing Activities	0.42	4.52	0.16	4.60	1.64	5.61	4.37	7.10	-3.41	5.00	2.04
Net Cash From Continuing Financing Activities	0.42	4.52	0.16	4.60	1.64	5.61	4.37	7.10	-3.41	5.00	2.04
Issuance of Common Equity	0.42	4.52	0.16	4.60	1.64	5.61	4.37	7.10	2.40	5.00	2.04
Effect of Exchange Rate Changes	0.11	-0.27	0.16	-0.00	-0.05	0.08	-0.09	-0.05	0.02	0.25	-0.09
Cash Income Taxes Paid	0.46	0.78	2.82	1.08	0.96	0.48	0.60	1.31	2.55	0.28	0.33

This table presents 10x Genomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Assets	919	965	1,029	1,019	929	606	124
Total Current Assets	584	596	635	748	774	481	106
Cash & Equivalents	344	359	220	587	664	424	65
Short-Term Investments	49	29	210	0.00	-	-	-
Accounts Receivable	88	115	104	85	51	33	28
Inventories, net	83	74	82	60	30	15	8.57
Prepaid Expenses	20	19	17	14	13	8.03	4.50
Plant, Property, & Equipment, net	253	280	289	169	73	49	11
Total Noncurrent Assets	82	90	105	102	82	76	6.95
Goodwill	4.51	4.51	4.51	4.51	0.00	-	-
Intangible Assets	16	17	23	25	22	-	-
Other Noncurrent Operating Assets	61	68	77	72	60	76	6.95
Total Liabilities & Shareholders' Equity	919	965	1,029	1,019	929	606	124
Total Liabilities	209	224	223	201	190	186	101
Total Current Liabilities	118	127	131	110	118	63	32
Accounts Payable	13	16	22	17	4.71	13	8.79
Accrued Expenses	41	57	60	51	43	24	9.94
Current Deferred Revenue	21	13	7.87	5.34	4.47	3.30	2.40
Current Employee Benefit Liabilities	34	30	33	32	15	12	7.05
Other Current Liabilities	9.29	12	9.04	5.13	50	0.00	-
Total Noncurrent Liabilities	91	97	92	91	72	123	69
Noncurrent Deferred Revenue	13	8.81	3.17	-	-	16	4.43
Other Noncurrent Operating Liabilities	78	88	89	91	72	87	39
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	710	741	806	818	739	420	-220
Total Preferred & Common Equity	710	741	806	818	739	420	-220
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	710	741	806	818	739	420	-220
Common Stock	2,178	2,026	1,839	1,681	1,544	682	11
Retained Earnings	-1,467	-1,284	-1,029	-863	-805	-262	-231
Accumulated Other Comprehensive Income / (Loss)	-0.49	-0.43	-4.34	0.02	-0.05	-0.05	-0.04

This table presents 10x Genomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	903	938	930	923	949	990	1,014	996
Total Current Assets	580	594	579	567	562	583	602	629
Cash & Equivalents	377	398	380	356	311	326	332	234
Short-Term Investments	50	0.00	0.27	16	46	66	86	218
Accounts Receivable	53	84	91	91	104	88	78	84
Inventories, net	75	94	88	83	81	84	82	79
Prepaid Expenses	26	18	20	21	20	19	21	14
Plant, Property, & Equipment, net	246	259	263	269	285	285	292	258
Total Noncurrent Assets	78	85	87	86	101	122	120	109
Goodwill	4.51	4.51	4.51	4.51	4.51	4.51	4.51	4.51
Intangible Assets	15	16	17	16	22	22	23	23
Other Noncurrent Operating Assets	58	64	66	66	75	95	93	81
Total Liabilities & Shareholders' Equity	903	938	930	923	949	990	1,014	996
Total Liabilities	196	215	206	204	203	196	212	220
Total Current Liabilities	108	121	111	109	105	98	112	127
Accounts Payable	10	26	21	20	19	23	29	22
Accrued Expenses	45	38	42	42	36	34	47	62
Current Deferred Revenue	21	18	16	14	11	9.22	8.53	6.67
Current Employee Benefit Liabilities	22	30	20	21	28	22	18	28
Other Current Liabilities	9.44	9.42	11	11	10	9.29	9.20	8.39
Total Noncurrent Liabilities	89	94	95	95	99	98	100	94
Noncurrent Deferred Revenue	13	12	11	9.79	-	-	-	-
Other Noncurrent Operating Liabilities	76	81	83	86	99	98	100	94
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	707	723	724	719	745	793	802	776
Total Preferred & Common Equity	707	723	724	719	745	793	802	776
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	707	723	724	719	745	793	802	776
Common Stock	2,209	2,141	2,107	2,064	1,981	1,937	1,884	1,793
Retained Earnings	-1,501	-1,418	-1,382	-1,344	-1,235	-1,142	-1,080	-1,012
Accumulated Other Comprehensive Income / (Loss)	-0.37	0.03	-0.43	-0.46	-0.68	-0.97	-1.48	-5.49

This table displays calculated financial ratios and metrics derived from 10x Genomics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	-1.28%	19.81%	5.28%	64.13%	21.53%	68.06%	105.83%	0.00%
EBITDA Growth	31.34%	-64.29%	-444.88%	95.17%	-2,077.72%	77.88%	-673.74%	0.00%
EBIT Growth	26.16%	-57.98%	-216.92%	90.04%	-1,632.19%	72.29%	-508.69%	0.00%
NOPAT Growth	26.67%	-57.99%	-221.41%	90.22%	-1,647.10%	72.40%	-502.80%	0.00%
Net Income Growth	28.41%	-53.67%	-185.11%	89.27%	-1,636.68%	72.22%	-499.54%	0.00%
EPS Growth	30.28%	-49.32%	-175.47%	90.13%	-571.25%	90.48%	-418.52%	0.00%
Operating Cash Flow Growth	143.85%	54.78%	-57.24%	90.19%	-729.27%	145.32%	-614.17%	0.00%
Free Cash Flow Firm Growth	39.03%	36.94%	-26.52%	49.22%	-587.96%	9.49%	0.00%	0.00%
Invested Capital Growth	-10.11%	-5.57%	62.87%	288.94%	129.76%	311.05%	0.00%	0.00%
Revenue Q/Q Growth	-3.01%	4.70%	2.52%	6.82%	14.10%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-1.55%	-15.12%	-4.90%	94.08%	-343.69%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-0.60%	-13.89%	-4.65%	88.09%	-302.75%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	2.68%	-13.76%	-4.52%	88.28%	-302.70%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-0.04%	-14.21%	0.74%	87.21%	-304.14%	0.00%	0.00%	0.00%
EPS Q/Q Growth	1.30%	-14.74%	2.01%	88.09%	-571.25%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-82.99%	44.19%	19.07%	86.42%	-168.93%	250.08%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-31.01%	27.71%	-11.02%	59.86%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-2.44%	-9.14%	15.56%	14.69%	1,973.47%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	67.86%	66.15%	76.69%	84.89%	80.44%	75.18%	80.41%	85.14%
EBITDA Margin	-24.96%	-35.88%	-26.17%	-5.06%	-171.92%	-9.59%	-72.89%	-19.39%
Operating Margin	-31.85%	-42.88%	-32.52%	-10.65%	-178.74%	-12.43%	-75.70%	-25.85%
EBIT Margin	-32.11%	-42.93%	-32.56%	-10.82%	-178.29%	-12.51%	-75.87%	-25.66%
Profit (Net Income) Margin	-29.90%	-41.23%	-32.15%	-11.87%	-181.61%	-12.71%	-76.88%	-26.39%
Tax Burden Percent	102.77%	102.55%	102.49%	108.39%	101.54%	100.70%	100.08%	100.11%
Interest Burden Percent	90.60%	93.65%	96.33%	101.24%	100.31%	100.89%	101.25%	102.76%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-40.71%	-51.20%	-39.04%	-25.40%	-884.57%	-317.31%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-28.84%	-34.31%	-29.55%	-21.99%	-853.15%	-312.73%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	15.54%	18.22%	18.59%	17.92%	790.93%	303.21%	0.00%	0.00%
Return on Equity (ROE)	-25.17%	-32.98%	-20.45%	-7.48%	-93.64%	-14.10%	-483.66%	0.00%
Cash Return on Invested Capital (CROIC)	-30.06%	-45.47%	-86.88%	-143.59%	-963.27%	-230.86%	0.00%	0.00%
Operating Return on Assets (OROA)	-20.82%	-26.64%	-16.42%	-5.45%	-69.41%	-8.42%	-89.30%	0.00%
Return on Assets (ROA)	-19.39%	-25.59%	-16.21%	-5.98%	-70.70%	-8.56%	-90.49%	0.00%
Return on Common Equity (ROCE)	-25.17%	-32.98%	-20.45%	-7.48%	-93.64%	-6.36%	4,574.93%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-25.72%	-34.42%	-20.60%	-7.12%	-73.43%	-7.44%	51.13%	0.00%
Net Operating Profit after Tax (NOPAT)	-136	-186	-118	-37	-374	-21	-78	-13
NOPAT Margin	-22.30%	-30.02%	-22.77%	-7.46%	-125.11%	-8.70%	-52.99%	-18.09%
Net Nonoperating Expense Percent (NNEP)	-11.87%	-16.89%	-9.49%	-3.41%	-31.42%	-4.58%	-197.44%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-19.18%	-25.06%	-14.59%	-	-	-	-	-
Cost of Revenue to Revenue	32.14%	33.85%	23.31%	15.11%	19.56%	24.82%	19.59%	14.86%
SG&A Expenses to Revenue	56.38%	55.49%	57.76%	52.51%	67.70%	53.21%	60.10%	65.75%
R&D to Revenue	43.34%	53.55%	51.45%	43.17%	191.04%	33.79%	75.11%	45.25%
Operating Expenses to Revenue	99.71%	109.04%	109.21%	95.55%	259.17%	87.61%	156.11%	110.99%
Earnings before Interest and Taxes (EBIT)	-196	-266	-168	-53	-533	-31	-111	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-152	-222	-135	-25	-514	-24	-107	-14
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.45	8.93	5.18	20.35	20.62	17.46	0.00	0.00
Price to Tangible Book Value (P/TBV)	2.52	9.19	5.36	21.13	21.26	17.46	0.00	0.00
Price to Revenue (P/Rev)	2.85	10.69	8.08	33.93	50.99	29.82	2.67	5.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.25	17.67	10.02	70.07	247.14	270.66	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.20	10.06	7.24	32.73	48.71	28.22	4.09	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	201.82	0.00	0.00	0.00	0.00	200.38	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.07	1.28	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.05	1.10	0.00
Financial Leverage	-0.54	-0.53	-0.63	-0.82	-0.93	-0.97	-1.52	0.00
Leverage Ratio	1.30	1.29	1.26	1.25	1.32	1.65	5.35	0.00
Compound Leverage Factor	1.18	1.21	1.22	1.27	1.33	1.66	5.41	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	6.61%	56.06%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	2.20%	7.91%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	4.41%	48.15%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	459.53%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	93.39%	-415.60%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-1.26	-0.28	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	16.72	0.33	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.84	-0.24	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-1.39	-0.38	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	18.43	0.46	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.93	-0.33	0.00
Altman Z-Score	3.34	16.16	10.36	49.48	46.11	24.13	-1.34	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	54.87%	1,045.90%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	4.97	4.69	4.85	6.77	6.56	7.63	3.28	0.00
Quick Ratio	4.09	3.96	4.08	6.10	6.05	7.26	2.88	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-101	-165	-262	-207	-407	-59	-65	0.00
Operating Cash Flow to CapEx	53.77%	-31.27%	-25.52%	-21.10%	-594.28%	81.01%	-1,215.93%	-284.85%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-238.76	-242.07	-19.22	-27.14	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-24.68	-129.55	11.25	-31.72	-13.19
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-141.63	-151.35	-2.64	-34.33	-17.82
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.62	0.50	0.50	0.39	0.67	1.18	0.00
Accounts Receivable Turnover	6.03	5.65	5.45	7.19	7.07	8.00	5.21	0.00
Inventory Turnover	2.50	2.70	1.70	1.65	2.59	5.12	3.34	0.00
Fixed Asset Turnover	2.30	2.18	2.25	4.05	4.91	8.20	13.15	0.00
Accounts Payable Turnover	13.71	11.22	6.18	6.72	6.59	5.59	3.26	0.00
Days Sales Outstanding (DSO)	60.56	64.61	66.96	50.77	51.65	45.61	70.07	0.00
Days Inventory Outstanding (DIO)	145.79	135.37	214.65	221.50	141.18	71.29	109.14	0.00
Days Payable Outstanding (DPO)	26.63	32.54	59.05	54.34	55.36	65.25	111.97	0.00
Cash Conversion Cycle (CCC)	179.72	167.44	222.56	217.94	137.46	51.65	67.24	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	317	352	373	229	59	26	-12	0.00
Invested Capital Turnover	1.83	1.71	1.72	3.41	7.07	36.46	-24.09	0.00
Increase / (Decrease) in Invested Capital	-36	-21	144	170	33	38	-12	0.00
Enterprise Value (EV)	1,345	6,226	3,738	16,051	14,557	6,939	598	0.00
Market Capitalization	1,738	6,615	4,171	16,640	15,237	7,333	390	390
Book Value per Share	$5.87	$6.27	$7.04	$7.32	$6.87	$4.37	($16.43)	$0.00
Tangible Book Value per Share	$5.70	$6.09	$6.80	$7.05	$6.66	$4.37	($16.43)	$0.00
Total Capital	710	741	806	818	739	450	53	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	30	30	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	20	25	0.00
Net Debt	-393	-389	-433	-588	-680	-394	-35	0.00
Capital Expenditures (CapEx)	12	49	132	101	37	43	6.28	3.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	73	80	71	49	-24	3.51	13	0.00
Debt-free Net Working Capital (DFNWC)	467	469	504	637	656	428	78	0.00
Net Working Capital (NWC)	467	469	504	637	656	418	74	0.00
Net Nonoperating Expense (NNE)	46	69	48	22	169	9.85	35	5.90
Net Nonoperating Obligations (NNO)	-393	-389	-433	-588	-680	-394	-35	0.00
Total Depreciation and Amortization (D&A)	44	44	33	28	19	7.17	4.36	4.45
Debt-free, Cash-free Net Working Capital to Revenue	12.01%	12.96%	13.84%	9.94%	-8.01%	1.43%	8.87%	0.00%
Debt-free Net Working Capital to Revenue	76.42%	75.78%	97.61%	129.92%	219.59%	173.93%	53.35%	0.00%
Net Working Capital to Revenue	76.42%	75.78%	97.61%	129.92%	219.59%	169.91%	50.49%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.52)	($2.18)	($1.46)	($0.53)	($5.37)	($0.80)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	120.45M	117.17M	113.86M	110.35M	108.75M	96.55M	0.00	0.00
Adjusted Diluted Earnings per Share	($1.52)	($2.18)	($1.46)	($0.53)	($5.37)	($0.80)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	120.45M	117.17M	113.86M	110.35M	108.75M	96.55M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($5.37)	($0.80)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	122.30M	119.17M	115.36M	112.84M	101.15M	39.09M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-136	-186	-118	-37	-374	-20	-56	-13
Normalized NOPAT Margin	-22.30%	-30.02%	-22.77%	-7.55%	-125.11%	-8.28%	-38.36%	-18.09%
Pre Tax Income Margin	-29.09%	-40.21%	-31.36%	-10.95%	-178.85%	-12.62%	-76.82%	-26.36%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-61.26	-316.77	-9.99	-46.08	-22.49
NOPAT to Interest Expense	0.00	0.00	0.00	-42.24	-222.29	-6.95	-32.19	-15.86
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-178.21	-338.57	-23.87	-48.69	-27.12
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-159.19	-244.09	-20.83	-34.79	-20.49
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.43%

This table displays calculated financial ratios and metrics derived from 10x Genomics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.84%	-10.30%	-1.30%	4.28%	5.01%	17.76%	17.22%	28.10%	17.28%	8.85%	4.61%
EBITDA Growth	46.36%	-5.87%	66.14%	41.69%	-13.71%	-170.25%	-150.13%	6.25%	-32.96%	-72.03%	-267.61%
EBIT Growth	40.53%	-2.30%	58.97%	35.57%	-16.88%	-121.80%	-128.97%	0.15%	-28.20%	-45.95%	-154.56%
NOPAT Growth	36.05%	9.69%	56.24%	34.13%	-18.29%	-138.95%	-137.01%	-0.38%	-24.57%	-45.90%	-151.88%
Net Income Growth	42.69%	-0.16%	61.55%	39.28%	-18.13%	-184.36%	-121.85%	3.17%	-19.65%	6.69%	-144.10%
EPS Growth	44.00%	4.76%	62.03%	39.62%	-13.64%	-200.00%	-113.51%	7.02%	-15.79%	17.65%	-146.67%
Operating Cash Flow Growth	318.45%	-126.20%	185.52%	165.04%	-281.21%	87.70%	-164.58%	32.05%	80.17%	136.40%	63.52%
Free Cash Flow Firm Growth	566.16%	104.08%	126.00%	116.86%	94.38%	88.86%	13.15%	11.74%	16.05%	11.62%	29.38%
Invested Capital Growth	-19.32%	-10.11%	-16.29%	-14.10%	-9.06%	-5.57%	20.10%	41.35%	42.74%	62.87%	61.65%
Revenue Q/Q Growth	-6.14%	8.81%	-0.95%	8.58%	-23.36%	19.74%	4.65%	9.33%	-14.05%	19.20%	14.36%
EBITDA Q/Q Growth	34.57%	-46.01%	7.24%	39.48%	-29.16%	53.30%	-59.71%	-18.04%	-206.95%	56.77%	40.14%
EBIT Q/Q Growth	29.03%	-32.99%	5.71%	33.17%	-22.08%	46.66%	-48.07%	-21.23%	-131.66%	44.94%	35.43%
NOPAT Q/Q Growth	21.09%	-20.14%	0.60%	32.13%	-11.43%	41.78%	-49.62%	-21.87%	-125.10%	42.25%	36.63%
Net Income Q/Q Growth	29.92%	-37.13%	5.66%	36.78%	-22.46%	47.36%	-48.98%	-22.99%	-194.78%	58.93%	34.97%
EPS Q/Q Growth	30.00%	-33.33%	6.25%	36.00%	-19.05%	46.84%	-49.06%	-20.45%	-214.29%	62.16%	35.09%
Operating Cash Flow Q/Q Growth	609.05%	-131.18%	188.70%	147.67%	-161.05%	201.79%	-119.54%	-179.42%	-130.06%	243.49%	43.62%
Free Cash Flow Firm Q/Q Growth	5,320.67%	-97.86%	25.30%	421.41%	52.54%	86.40%	18.72%	-7.20%	5.96%	-5.99%	17.40%
Invested Capital Q/Q Growth	-11.60%	-2.44%	-5.62%	-0.88%	-1.51%	-9.14%	-3.15%	4.93%	2.27%	15.56%	13.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	68.08%	67.24%	70.16%	68.07%	65.89%	62.93%	62.18%	67.85%	73.27%	76.43%	76.82%
EBITDA Margin	-17.68%	-25.36%	-18.90%	-20.18%	-36.20%	-21.48%	-55.08%	-36.09%	-33.43%	-9.36%	-25.81%
Operating Margin	-25.39%	-30.20%	-27.36%	-27.26%	-43.61%	-30.00%	-61.70%	-43.15%	-38.71%	-14.78%	-30.51%
EBIT Margin	-24.01%	-31.76%	-25.98%	-27.30%	-44.35%	-27.84%	-62.51%	-44.18%	-39.84%	-14.78%	-32.00%
Profit (Net Income) Margin	-22.18%	-29.71%	-23.58%	-24.75%	-42.52%	-26.61%	-60.52%	-42.51%	-37.79%	-11.02%	-31.98%
Tax Burden Percent	102.54%	101.34%	103.82%	102.21%	103.71%	105.05%	101.35%	102.71%	102.20%	104.90%	104.69%
Interest Burden Percent	90.09%	92.32%	87.39%	88.72%	92.43%	90.96%	95.52%	93.69%	92.80%	71.06%	95.44%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-35.42%	-38.60%	-33.85%	-32.39%	-52.41%	-35.82%	-71.83%	-50.23%	-44.78%	-17.75%	-41.17%
ROIC Less NNEP Spread (ROIC-NNEP)	-33.71%	-34.98%	-32.07%	-30.14%	-48.15%	-33.30%	-65.25%	-46.18%	-41.79%	-17.54%	-38.53%
Return on Net Nonoperating Assets (RNNOA)	18.88%	18.85%	16.51%	15.36%	25.09%	17.68%	34.76%	26.16%	24.94%	11.03%	25.75%
Return on Equity (ROE)	-16.53%	-19.75%	-17.34%	-17.03%	-27.33%	-18.13%	-37.06%	-24.07%	-19.85%	-6.71%	-15.42%
Cash Return on Invested Capital (CROIC)	-17.11%	-30.06%	-21.55%	-32.46%	-43.32%	-45.47%	-64.21%	-70.81%	-73.66%	-86.88%	-90.16%
Operating Return on Assets (OROA)	-16.43%	-20.59%	-17.35%	-17.97%	-28.64%	-17.28%	-37.99%	-25.22%	-21.18%	-7.46%	-16.23%
Return on Assets (ROA)	-15.17%	-19.27%	-15.74%	-16.29%	-27.46%	-16.51%	-36.78%	-24.27%	-20.09%	-5.56%	-16.21%
Return on Common Equity (ROCE)	-16.53%	-19.75%	-17.34%	-17.03%	-27.33%	-18.13%	-37.06%	-24.07%	-19.85%	-6.71%	-15.42%
Return on Equity Simple (ROE_SIMPLE)	-22.21%	0.00%	-25.26%	-33.12%	-36.77%	0.00%	-29.97%	-21.72%	-21.73%	0.00%	-21.56%
Net Operating Profit after Tax (NOPAT)	-28	-35	-29	-29	-43	-39	-66	-44	-36	-16	-28
NOPAT Margin	-17.77%	-21.14%	-19.15%	-19.08%	-30.53%	-21.00%	-43.19%	-30.21%	-27.10%	-10.35%	-21.36%
Net Nonoperating Expense Percent (NNEP)	-1.71%	-3.62%	-1.78%	-2.25%	-4.26%	-2.51%	-6.57%	-4.05%	-2.99%	-0.21%	-2.64%
Return On Investment Capital (ROIC_SIMPLE)	-3.89%	-4.91%	-	-	-	-5.21%	-	-	-	-2.01%	-
Cost of Revenue to Revenue	31.92%	32.76%	29.84%	31.93%	34.11%	37.07%	37.82%	32.15%	26.73%	23.57%	23.18%
SG&A Expenses to Revenue	57.93%	56.86%	53.88%	54.24%	60.83%	46.81%	53.64%	62.33%	62.02%	50.49%	56.00%
R&D to Revenue	41.48%	40.58%	43.63%	41.09%	48.68%	46.12%	70.23%	48.67%	49.97%	40.72%	51.34%
Operating Expenses to Revenue	93.47%	97.44%	97.51%	95.33%	109.51%	92.93%	123.87%	111.00%	111.98%	91.21%	107.34%
Earnings before Interest and Taxes (EBIT)	-37	-52	-39	-42	-63	-51	-96	-65	-54	-23	-42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-42	-29	-31	-51	-40	-85	-53	-45	-15	-34
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.51	2.45	3.76	3.22	6.17	8.93	6.50	8.18	8.02	5.18	4.18
Price to Tangible Book Value (P/TBV)	1.55	2.52	3.87	3.31	6.35	9.19	6.74	8.46	8.31	5.36	4.34
Price to Revenue (P/Rev)	1.71	2.85	4.32	3.69	7.09	10.69	8.20	11.41	12.00	8.08	6.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.29	4.25	7.15	5.66	11.71	17.67	11.57	15.22	15.76	10.02	8.64
Enterprise Value to Revenue (EV/Rev)	1.03	2.20	3.69	3.08	6.50	10.06	7.59	10.72	11.22	7.24	5.54
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	11.29	201.82	59.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.56	-0.54	-0.51	-0.51	-0.52	-0.53	-0.53	-0.57	-0.60	-0.63	-0.67
Leverage Ratio	1.28	1.30	1.29	1.26	1.27	1.29	1.28	1.26	1.25	1.26	1.26
Compound Leverage Factor	1.15	1.20	1.12	1.12	1.18	1.17	1.22	1.18	1.16	0.90	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.12	3.85	6.61	5.85	12.05	16.90	13.34	19.16	17.69	10.83	8.38
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.37	4.97	4.90	5.22	5.22	4.69	5.37	5.94	5.37	4.85	4.96
Quick Ratio	4.44	4.09	3.97	4.25	4.26	3.96	4.40	4.88	4.43	4.08	4.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	40	0.73	34	27	-8.47	-18	-131	-161	-151	-160	-151
Operating Cash Flow to CapEx	1,814.63%	-248.45%	556.47%	260.46%	-540.38%	746.61%	-166.08%	-45.46%	-90.48%	34.54%	-26.15%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-8,473.60	0.00	0.00	0.00	-7,929.03	0.00	-1,325.81
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-15,725.00	0.00	0.00	0.00	-217.11	0.00	-83.89
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-18,635.00	0.00	0.00	0.00	-457.05	0.00	-404.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.68	0.65	0.67	0.66	0.65	0.62	0.61	0.57	0.53	0.50	0.51
Accounts Receivable Turnover	8.68	6.03	6.72	7.06	7.39	5.65	6.31	6.94	6.94	5.45	6.22
Inventory Turnover	2.50	2.50	2.41	2.60	2.68	2.70	2.23	1.95	1.79	1.70	1.71
Fixed Asset Turnover	2.42	2.30	2.32	2.30	2.23	2.18	2.18	2.24	2.22	2.25	2.52
Accounts Payable Turnover	13.05	13.71	9.34	10.06	8.95	11.22	8.81	6.03	5.42	6.18	5.75
Days Sales Outstanding (DSO)	42.03	60.56	54.30	51.67	49.38	64.61	57.87	52.62	52.57	66.96	58.69
Days Inventory Outstanding (DIO)	145.80	145.79	151.74	140.55	136.29	135.37	163.54	187.39	203.71	214.65	213.06
Days Payable Outstanding (DPO)	27.96	26.63	39.07	36.27	40.79	32.54	41.44	60.53	67.35	59.05	63.43
Cash Conversion Cycle (CCC)	159.86	179.72	166.98	155.95	144.88	167.44	179.97	179.48	188.93	222.56	208.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	280	317	325	344	347	352	388	400	382	373	323
Invested Capital Turnover	1.99	1.83	1.77	1.70	1.72	1.71	1.66	1.66	1.65	1.72	1.93
Increase / (Decrease) in Invested Capital	-67	-36	-63	-56	-35	-21	65	117	114	144	123
Enterprise Value (EV)	641	1,345	2,323	1,948	4,065	6,226	4,486	6,095	6,015	3,738	2,791
Market Capitalization	1,068	1,738	2,721	2,328	4,436	6,615	4,844	6,488	6,436	4,171	3,244
Book Value per Share	$5.78	$5.87	$6.00	$6.05	$6.02	$6.27	$6.35	$6.83	$6.96	$7.04	$6.81
Tangible Book Value per Share	$5.62	$5.70	$5.83	$5.87	$5.85	$6.09	$6.12	$6.60	$6.72	$6.80	$6.56
Total Capital	707	710	723	724	719	741	745	793	802	806	776
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-427	-393	-398	-380	-372	-389	-357	-393	-421	-433	-453
Capital Expenditures (CapEx)	1.89	2.72	3.89	2.88	2.91	3.45	15	25	4.56	40	37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	45	73	74	88	87	80	100	92	69	71	50
Debt-free Net Working Capital (DFNWC)	472	467	473	468	458	469	458	485	490	504	503
Net Working Capital (NWC)	472	467	473	468	458	469	458	485	490	504	503
Net Nonoperating Expense (NNE)	6.83	14	6.71	8.68	17	10	27	18	14	1.05	14
Net Nonoperating Obligations (NNO)	-427	-393	-398	-380	-372	-389	-357	-393	-421	-433	-453
Total Depreciation and Amortization (D&A)	9.81	11	11	11	11	12	11	12	8.62	8.47	8.12
Debt-free, Cash-free Net Working Capital to Revenue	7.19%	12.01%	11.83%	13.94%	13.84%	12.96%	16.96%	16.18%	12.89%	13.84%	9.86%
Debt-free Net Working Capital to Revenue	75.53%	76.42%	75.06%	74.10%	73.29%	75.78%	77.44%	85.30%	91.36%	97.61%	99.77%
Net Working Capital to Revenue	75.53%	76.42%	75.06%	74.10%	73.29%	75.78%	77.44%	85.30%	91.36%	97.61%	99.77%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.28)	($0.40)	($0.30)	($0.32)	($0.50)	($0.42)	($0.79)	($0.53)	($0.44)	($0.14)	($0.37)
Adjusted Weighted Average Basic Shares Outstanding	122.61M	120.45M	120.73M	120.07M	119.39M	117.17M	117.73M	116.71M	115.62M	113.86M	114.11M
Adjusted Diluted Earnings per Share	($0.28)	($0.40)	($0.30)	($0.32)	($0.50)	($0.42)	($0.79)	($0.53)	($0.44)	($0.14)	($0.37)
Adjusted Weighted Average Diluted Shares Outstanding	122.61M	120.45M	120.73M	120.07M	119.39M	117.17M	117.73M	116.71M	115.62M	113.86M	114.11M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	123.13M	122.30M	121.05M	120.49M	119.71M	119.17M	118.21M	117.42M	116.19M	115.36M	114.46M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-35	-29	-29	-43	-39	-66	-44	-36	-16	-28
Normalized NOPAT Margin	-17.77%	-21.14%	-19.15%	-19.08%	-30.53%	-21.00%	-43.19%	-30.21%	-27.10%	-10.35%	-21.36%
Pre Tax Income Margin	-21.63%	-29.32%	-22.71%	-24.22%	-40.99%	-25.33%	-59.71%	-41.39%	-36.98%	-10.50%	-30.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-62,538.00	0.00	0.00	0.00	-2,816.00	0.00	-367.95
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-43,048.60	0.00	0.00	0.00	-1,915.35	0.00	-245.59
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-65,448.00	0.00	0.00	0.00	-3,055.95	0.00	-688.75
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-45,958.60	0.00	0.00	0.00	-2,155.29	0.00	-566.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About 10x Genomics' Financials

When does 10x Genomics's financial year end?

According to the most recent income statement we have on file, 10x Genomics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has 10x Genomics' net income changed over the last 7 years?

10x Genomics' net income appears to be on an upward trend, with a most recent value of -$182.63 million in 2024, rising from -$18.76 million in 2017. The previous period was -$255.10 million in 2023. See 10x Genomics' forecast for analyst expectations on what’s next for the company.

What is 10x Genomics's operating income?

10x Genomics's total operating income in 2024 was -$194.56 million, based on the following breakdown:

Total Gross Profit: $414.48 million
Total Operating Expenses: $609.04 million

How has 10x Genomics revenue changed over the last 7 years?

Over the last 7 years, 10x Genomics' total revenue changed from $71.09 million in 2017 to $610.79 million in 2024, a change of 759.2%.

How much debt does 10x Genomics have?

10x Genomics' total liabilities were at $208.50 million at the end of 2024, a 7.0% decrease from 2023, and a 106.3% increase since 2018.

How much cash does 10x Genomics have?

In the past 6 years, 10x Genomics' cash and equivalents has ranged from $65.08 million in 2018 to $663.60 million in 2020, and is currently $344.07 million as of their latest financial filing in 2024.

How has 10x Genomics' book value per share changed over the last 7 years?

Over the last 7 years, 10x Genomics' book value per share changed from 0.00 in 2017 to 5.87 in 2024, a change of 586.6%.

Related Companies

This page (NASDAQ:TXG) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Financials

Frequently Asked Questions About 10x Genomics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Financials

Annual Income Statements for 10x Genomics

Quarterly Income Statements for 10x Genomics

Annual Cash Flow Statements for 10x Genomics

Quarterly Cash Flow Statements for 10x Genomics

Annual Balance Sheets for 10x Genomics

Quarterly Balance Sheets for 10x Genomics

Annual Metrics And Ratios for 10x Genomics

Quarterly Metrics And Ratios for 10x Genomics

Frequently Asked Questions About 10x Genomics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools